GlassScriptPhysician profile
Lina Wu
NPI 1114285426
$5,044.08
in general payments reported to CMS, 2019-2025
24 companies · $873 in 2025
The $873 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,053 · 2022: $625 · 2023: $669 · 2024: $823 · 2025: $873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,365.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $613.96 | 2021-2025 | Jardiance |
| Esperion Therapeutics, INC. | $589.94 | 2021-2025 | Nexletol |
| Glaxosmithkline, LLC. | $434.19 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $424.75 | 2021-2024 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $398.02 | 2021-2025 | Evenity, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $376.77 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $360.86 | 2021-2025 | Xifaxan, Trulance |
| Abbvie INC. | $342.80 | 2021-2025 | |
| Exact Sciences Corporation | $266.80 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $171.65 | 2021-2024 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Gilead Sciences, INC. | $171.30 | 2021-2025 | |
| Radius Health, INC. | $134.34 | 2023-2025 | Tymlos, Binosto |
| Pfizer INC. | $125.07 | 2023-2024 | |
| Amarin Pharma, INC. | $124.04 | 2021-2022 | |
| Novo Nordisk INC | $110.68 | 2021-2023 | Rybelsus, Ozempic |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $99.77 | 2021-2022 | |
| Horizon Therapeutics Plc | $78.86 | 2021-2022 | |
| Astellas Pharma US INC | $66.48 | 2021-2024 | Veozah |
| Phadia US INC. | $43.26 | 2024-2025 | Immunocap |
| Verona Pharma, INC. | $38.41 | 2025 | Ohtuvayre |
| Philips North America LLC | $22.92 | 2025 | Vest Therapy Und |
| Baxter Healthcare | $18.82 | 2023 | Hillrom - Vest System Model 105 Home Care |
| Ironwood Pharmaceuticals, INC | $15.39 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $15.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lina Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.